High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS

Schiffer, Eric; Mischak, Harald; Novák, Jan

doi:10.1002/pmic.200600230

Cited by 95 publications

(73 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Candesartan treatment resulted in a significant change in 15 of 113 proteins that are characteristic for diabetic renal damage. Similar data have been obtained in patients with vasculitis (Haubitz et al, manuscript in preparation) (85), where therapy improved/changed the vasculitisspecific protein pattern toward a normal urinary proteome.…”

Section: Identification Of "Biomarkers" For Kidney Diseasessupporting

confidence: 70%

Advances in Urinary Proteome Analysis and Biomarker Discovery

Fliser¹,

Novák²,

Thongboonkerd³

et al. 2007

Journal of the American Society of Nephrology

Self Cite

256

206

View full text Add to dashboard Cite

Noninvasive diagnosis of kidney diseases and assessment of the prognosis are still challenges in clinical nephrology. Definition of biomarkers on the basis of proteome analysis, especially of the urine, has advanced recently and may provide new tools to solve those challenges. This article highlights the most promising technological approaches toward deciphering the human proteome and applications of the knowledge in clinical nephrology, with emphasis on the urinary proteome. The data in the current literature indicate that although a thorough investigation of the entire urinary proteome is still a distant goal, clinical applications are already available. Progress in the analysis of human proteome in health and disease will depend more on the standardization of data and availability of suitable bioinformatics and software solutions than on new technological advances. It is predicted that proteomics will play an important role in clinical nephrology in the very near future and that this progress will require interactive dialogue and collaboration between clinicians and analytical specialists.

show abstract

Section: Identification Of "Biomarkers" For Kidney Diseasessupporting

confidence: 70%

Advances in Urinary Proteome Analysis and Biomarker Discovery

Fliser¹,

Novák²,

Thongboonkerd³

et al. 2007

Journal of the American Society of Nephrology

Self Cite

256

206

View full text Add to dashboard Cite

show abstract

“…In this study, we focused on the urinary proteome, because urine can be easily sampled and contains an array of low-molecular-weight proteins and peptides that can be analysed without additional manipulation, such as proteolysis. 3 Capillary electrophoresis coupled to mass spectrometry (CE-MS) 4,5 is now an established method, which allowed identifying peptide markers specific for a variety of diseases, such as diabetes and diabetic nephropathy, 6 graft rejection, 7 and coronary artery disease. 8 One of the core features of cardiac remodelling in hypertensive patients at risk of developing HF and patients with overt HF is related to increased interstitial deposition and cross-linking of type-I collagen.…”

Section: Introductionmentioning

confidence: 99%

Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction

Кузнецова

Mischak

Mullen

et al. 2013

European Heart Journal

View full text Add to dashboard Cite

AimsDespite the significant heart failure (HF) burden on society, easily applicable screening techniques, particularly for the early detection of asymptomatic left ventricular (LV) dysfunction, are lacking. The present study aimed to identify and test a set of urinary polypeptides that may indicate early LV diastolic dysfunction as defined by echocardiography in hypertensive patients in a cross-sectional case -control study nested within the FLEMish study on ENvironment, Genes and Health Outcome (FLEMENGHO). Methods and resultsTo identify potentially discriminating urinary biomarkers for LV diastolic dysfunction, we applied capillary electrophoresis coupled to mass spectrometry. In the discovery set, we compared 19 hypertensive patients with asymptomatic LV diastolic dysfunction with 19 healthy controls. In the absence of adjustment for multiple testing, 85 urinary peptides were different between cases and controls at a P-value of ,0.033. With adjustment for multiple testing, three potential biomarkers remained significantly different between cases and controls (P ≤ 0.02). We combined the 85 potential biomarkers in a high-dimensional model (classifier), which we applied in a blinded manner to an independent test set of 16 hypertensive patients with symptomatic HF and 16 healthy controls. Upon unblinding, the area under the receiver operating characteristic curve (AUC) of the HF classification was 0.84 (95% CI: 0.70 -0.98; P ¼ 0.001). ConclusionIn asymptomatic hypertensive patients with LV diastolic dysfunction, we identified a set of urinary polypeptides specific for essential hypertension with LV diastolic dysfunction that subsequently distinguished hypertensive patients with overt HF from healthy controls.--

show abstract

“…Many of the high-throughput methods directly detect native peptides and proteins present in tissues or body fluids [20,21]. Because the termini of these naturally occurring polypeptides have not been generated by defined enzymatic cleavage and they frequently harbor PTM, direct identification of the polypeptide is challenging and often without success (e.g.…”

Section: Ideally All Peptide/protein Biomarkers Should Be Sequencedmentioning

confidence: 99%

Clinical proteomics: A need to define the field and to begin to set adequate standards

Mischak

Apweiler

Banks

et al. 2007

Proteomics Clinical Apps

Self Cite

284

273

View full text Add to dashboard Cite

The aim of this manuscript is to initiate a constructive discussion about the definition of clinical proteomics, study requirements, pitfalls and (potential) use. Furthermore, we hope to stimulate proposals for the optimal use of future opportunities and seek unification of the approaches in clinical proteomic studies. We have outlined our collective views about the basic principles that should be considered in clinical proteomic studies, including sample selection, choice of technology and appropriate quality control, and the need for collaborative interdisciplinary efforts involving clinicians and scientists. Furthermore, we propose guidelines for the critical aspects that should be included in published reports. Our hope is that, as a result of stimulating discussion, a consensus will be reached amongst the scientific community leading to guidelines for the studies, similar to those already published for mass spectrometric sequencing data. We contend that clinical proteomics is not just a collection of studies dealing with analysis of clinical samples. Rather, the essence of clinical proteomics should be to address clinically relevant questions and to improve the state-of-the-art, both in diagnosis and in therapy of diseases.

show abstract

High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS

Cited by 95 publications

References 106 publications

Advances in Urinary Proteome Analysis and Biomarker Discovery

Advances in Urinary Proteome Analysis and Biomarker Discovery

Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction

Clinical proteomics: A need to define the field and to begin to set adequate standards

Contact Info

Product

Resources

About